# A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

> **NCT05650385** · PHASE1 · UNKNOWN · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 68 (estimated)

## Conditions studied

- Neoplasms Malignant

## Interventions

- **DRUG:** B1962

## Key facts

- **NCT ID:** NCT05650385
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-12
- **Final completion:** 2025-10
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650385, "A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05650385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*